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Abstract 
Background: In low-income countries, like Malawi, important public 
health measures including social distancing or a lockdown have been 
challenging to implement owing to socioeconomic constraints, 
leading to predictions that the COVID-19 pandemic would progress 
rapidly. However, due to limited capacity to test for severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, there are 
no reliable estimates of the true burden of infection and death.  We, 
therefore, conducted a SARS-CoV-2 serosurvey amongst health care 
workers (HCWs) in Blantyre city to estimate the cumulative incidence 
of SARS-CoV-2 infection in urban Malawi. 
Methods: We recruited 500 otherwise asymptomatic HCWs from 
Blantyre City (Malawi) from 22nd May 2020 to 19th June 2020 and 
serum samples were collected from all participants. A commercial 
ELISA was used to measure SARS-CoV-2 IgG antibodies in serum. 
Results: A total of 84 participants tested positive for SARS-CoV-2 
antibodies. The HCWs with positive SARS-CoV-2 antibody results came 
from different parts of the city. The adjusted seroprevalence of SARS-
CoV-2 antibodies was 12.3% [CI 8.2 - 16.5]. Using age-stratified 
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infection fatality estimates reported from elsewhere, we found that at 
the observed adjusted seroprevalence, the number of predicted 
deaths was eight times the number of reported deaths. 
Conclusions: The high seroprevalence of SARS-CoV-2 antibodies 
among HCWs and the discrepancy in the predicted versus reported 
deaths suggests that there was early exposure but slow progression 
of COVID-19 epidemic in urban Malawi. This highlights the urgent 
need for development of locally parameterised mathematical models 
to more accurately predict the trajectory of the epidemic in sub-
Saharan Africa for better evidence-based policy decisions and public 
health response planning.
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Introduction
Coronavirus disease 2019 (COVID-19) has had a dramatic 
impact worldwide, with high mortality in Asia, Europe and 
the Americas1. Africa reported its first COVID-19 case on 
14th February 20202. Due to poor socio-economic conditions, 
high HIV prevalence, an increase in non-communicable diseases 
and challenged health system infrastructure, it was predicted that 
the African pandemic would progress rapidly. As of 16th July 
2020, however, the number of COVID-19 cases was 665,522 and 
deaths 14,4341,2, much lower than predicted by mathematical 
models3.
In low-income countries, like Malawi, important public health 
measures like social distancing or a lockdown are difficult to 
implement owing to socioeconomic constraints. Furthermore, 
the limited capacity to test for severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) infection impedes effective 
public health response planning. Initial testing in Malawi focused 
on case identification in patients with COVID-19-like symp-
toms, contacts of index patients and inbound travellers. The first 
COVID-19 case in Malawi was reported on 2nd April and as of 16th 
July 2020 there were 2716 cases with only 51 deaths reported2,4. 
Given the sampling strategy, the true burden is certainly much 
greater than the reported cases, but there are no reliable estimates 
of the true burden of infection and death. Up to now, health serv-
ices have reported only small number of cases and have not been 
overwhelmed as predicted3.
The unrestricted nature of the COVID-19 epidemic in 
Malawi provides an opportunity to compare its trajectory in a 
low-income setting with what has been reported in high income 
settings. It has been shown that the rate of asymptomatic 
SARS-CoV-2 infection among health care workers (HCWs) 
reflects general community transmission rather than in-hospital 
exposure5. We, therefore, conducted a SARS-CoV-2 serosurvey 
amongst HCWs in Blantyre city to estimate the cumulative 
incidence of SARS-CoV-2 infection in urban Malawi.
Methods
Ethical statement
Ethical approval was provided by the College of Medi-
cine Research and Ethics Committee (COMREC, Malawi) 
(P.05/20/3045) and Liverpool School of Tropical Medicine 
(LSTM, UK) (20-043). All participants gave informed written 
consent for participation in the study, publication of the data and 
storage/usage of collected samples.
Study setting and participants
Participant recruitment was done at the Malawi-Liverpool- 
Wellcome Trust Clinical Research programme (MLW) in 
Blantyre, Malawi, as part of an ongoing longitudinal study that 
seeks to investigate markers of SARS-CoV-2 exposure and 
immunological protection in Malawian adults. The study site is 
within the compound of the Queen Elizabeth Central Hospital 
(QECH), the largest tertiary teaching hospital in Malawi. It 
is easily accessible from most parts of the city. Participants 
were HCWs from Blantyre City, both clinical and non-clinical. 
We used a convenience sampling approach, whereby the study 
was advertised electronically and by word of mouth. The sam-
ple size was calculated based on the study primary objective, 
which was to compare the SARS CoV-2 neutralising antibody 
titers in recovered COVID-19 patients compared to SARS 
CoV-2 antibody positive (asymptomatic/mild) individuals. 
Inclusion criteria for the study included being an HCW resident 
in Blantyre, aged between 18 and 65 years old, and otherwise 
asymptomatic. The exclusion criterion was withholding consent. 
Electronic case report forms (eCRFs) were used to collect demo-
graphic data including age, gender, place of residence, com-
mon mode of transportation, occupation and involvement in 
COVID-19 work. The samples used for this manuscript are from 
the baseline recruitment arm of the asymptomatic group in the 
main study.
Sample collection, processing and experimental setup
Peripheral blood (10ml), 7ml in Sodium Heparin tubes and 
3ml in serum separation tubes (SST) (All BD Biosciences), 
was collected from all study participants using venesection by 
the study clinical team at the study site (MLW) between 22nd 
May 2020 and 19th June 2020. Serum was collected from the 
SSTs by centrifugation at 500g for 8 mins and stored at -80°C. 
To measure SARS-CoV-2 antibodies, we used a commercial 
enzyme linked-immunosorbent assay (ELISA) targeting Spike 
(S2) and Nucleoprotein (N) from SARS-CoV-2 (Omega diag-
nostics, UK; ODL 150/10; Lot #103183). The assay was per-
formed as per the manufacturer’s instructions. In brief, participant 
serum was diluted (1:200) in sample diluent (150mM Tris- 
buffered saline, pH 7.2 with antimicrobial agent). The diluted 
samples, diluent alone (negative control), manufacturer’s cut-
off control and positive control were added at 100μl per well. 
The plate was incubated at room temperature for 30 mins. After 
incubation, the plate was washed three times with wash buffer 
(100mM Tris-buffered saline with detergent, pH 7.2) using a 
plate washer (Asys Atlantis, Biochrom Ltd, UK). Human IgG 
conjugated to horseradish peroxidase was then added to 
each well at 100μl and incubated for 30 minutes at room 
temperature. After incubation, the plate was washed four 
times with wash buffer, and 100μl of TMB (3,3’,5,5’-Tetrameth-
ylbenzidine) Substrate (aqueous solution of TMB and hydrogen 
peroxide) was added. The plate was incubated for 10 minutes at 
room temperature, before addition of 100μl of Stop Solution 
(0.25M sulphuric acid). The optical density (OD) of each well 
was read at 450nm in a microplate reader (BioTek ELx808, 
UK) within 10 minutes. The assay interpretation was as fol-
lows; positive result (OD 0.6), indeterminate result (OD 0.55 
to < 0.6) and negative (OD < 0.55) This assay has undergone 
rigorous independent validation at the Liverpool School of 
Tropical Medicine (UK) and St George’s University of London 
(UK)6.
Statistical analysis
Graphical presentation was performed using GraphPad Prism 
8 (GraphPad Software, USA). To integrate uncertainty aris-
ing from test sensitivity and specificity, we used a method 
published by Reiczigel et al., 20107. The geospatial data 
was plotted in R (v4.0.0) using ggmap (v3.0.0)8 and ggplot2 
(v3.3.1)9.
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Results
Demographics of study participants
We recruited 500 asymptomatic HCWs with a median age of 
31 (range 20–64 years)10. The average household size for the 
participants was four [confidence interval (CI) 3–5]. Of the 
500, 331 were clinical HCWs and 169 non-clinical HCWs 
(Table 1). The clinical HCWs included nurses, medical 
doctors and clinical officers, while the non-clinical HCWs 
included clerical/administration, field workers and laboratory 
scientists. The primary workstation for the HCWs included pri-
mary healthcare facilities (35/500), secondary healthcare facili-
ties (291/500), and clinical research facilities (174/500). The 
majority of the participants were nurses (57%), 41% of all par-
ticipants were involved in clinical work related to COVID-19 and 
73% of the total participants used public transport or walking as 
their main means of transport. The main characteristics of the 
participants are summarised in Table 1.
Seroprevalence of SARS CoV-2 antibodies and 
geospatial location of the antibody positive individuals
84 participants tested positive for SARS-CoV-2 antibodies 
(Figure 1). After adjusting for test sensitivity and specificity6,7, 
the overall seroprevalence of SARS-CoV-2 antibodies was 
12.3% [CI 8.2 - 16.5]. This suggests that local transmission 
was high and that SARS-CoV-2 may have been circulating for 
some time in Blantyre City.
To estimate the potential geographical spread of SARS-CoV-2, 
we plotted the geographical coordinates of place of residence 
for the individuals with a positive antibody result on the map 
of Blantyre City. We found that the HCWs with a positive 
SARS-CoV-2 antibody result came from different parts of 
the city (Figure 2). This suggests that SARS-CoV-2 local trans-
mission was likely widespread across the city.
Crude projections of mortality based on seroprevalence 
estimates
Using estimates of infection fatality rates from Verity et al.11 
and the Malawi population census12, we estimated the number 
of deaths that could have occurred at the observed seropreva-
lence of SARS-CoV-2 antibodies (Table 2). We adjusted 
the population estimates by inflating them to take into account 
population annual population growth rate of 2% from 2018 to 
202012. We assumed that there was a uniform risk of infection 
at all age groups and that the seroprevalence was similar to the 
general population.
The crude estimates suggest that there should have been at 
least 138 deaths by 19th June 2020. However, four weeks 
following the serosurvey, only 17 COVID-confirmed deaths 
in Blantyre have been reported by the Public Health Institute of 
Malawi4, which is approximately eight times below the pre-
dicted deaths. When the seroprevalence is extrapolated to the 
entire Malawi, it predicts approximately 5,295 COVID-19 
deaths, but only 51 deaths have been reported as of 16th July 
2020. These crude estimates highlight a discrepancy between the 
predicted deaths using infection fatality rates from else-
where and the actual number of reported COVID-19 deaths in 
Malawi.
Conclusions
To our knowledge, this seroprevalence study is the first to 
report estimates of SARS-CoV-2 exposure among HCWs in an 
African urban low-income setting. It provides insights into the 
potentially unique trajectory of the COVID-19 epidemic in 
sub-Saharan Africa (SSA), using data from urban Malawi. 
We observe a high seroprevalence of SARS-CoV-2 anti-
bodies amongst HCWs. It has been reported elsewhere that 
HCWs accounted for a high proportion of cases early in the 
SARS-CoV-2 outbreak when transmission was increasing 
sharply and personal protective equipment (PPE) provision was 
patchy13–15. Our data could suggest that Malawi is relatively early 
in the epidemic and that COVID-19 cases are likely to continue 
Table 1. Study participant demographics.
Characteristics Number of 
participants
Proportion
Gender
Male 236 47%
Female 264 53%
Age
20–29 209 42%
30–39 170 34%
40–49 86 17%
50–59 28 6%
60+ 7 1%
Occupation
Clinical HCW 331 66%
Non-clinical 
HCW
169 34%
COVID-19 work
Clinical 205 41%
Non-clinical 43 9%
None 252 50%
Transport
Public + walking 363 73%
Private 137 27%
COVID-19, coronavirus diseases 2019; HCW, health care 
workers.
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Figure 1. SARS-CoV-2 serological results from asymptomatic health care workers. We used a commercial ELISA to measure SARS-
CoV-2 antibodies against Spike (S2) and Nucleoprotein (N). OD, optical density.
to rise sharply in the coming weeks, but the serology also 
suggests that large numbers of cases must be either asympto-
matic or only show mild disease.
The discrepancy between the predicted compared to reported mor-
tality at the observed seroprevalence estimate may also suggest 
that there are large numbers of underreported or misclassified 
deaths in Malawi. However, even in countries like South Africa 
with relatively abundant testing capacity and strong health 
systems, there is relatively low mortality with a case fatality 
ratio of 1.516. This may imply that the impact of SARS-CoV-2 
in Africa is potentially much less severe or is following 
a different trajectory than that experienced in China, Americas 
and Europe, where case fatality ratios were commonly above 
five1. This warrants further investigation.
However, the reasons behind the discrepancy in the COVID-
19 pandemic trajectory between SSA and elsewhere might 
include population demography, climate and prior cross-reactive 
immunity17. In Malawi, for example, the population is younger 
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Figure 2. Map of Blantyre showing geospatial distribution of seropositive results. We collected geocoordinate data for the place of 
residence of all study participants at recruitment. The geocoordinates were combined with the ELISA assay results and plotted on the map 
of Blantyre using R. Black dot, seronegative; Orange dot, indeterminate; Red dot, seropositive.
Table 2. Crude estimates of predicted mortality at the observed seroprevalence.
Age
Population* 
(Blantyre)
Population* 
(Malawi)
Infection 
fatality rate 
✟
Number of 
Infections Deaths
Blantyre Malawi Blantyre Malawi
0–9 yrs 207,002 5,394,769 0.00% 24,840 663,557 0 11
10–19 yrs 199,915 4,753,846 0.01% 23,990 584,723 2 41
20–29 yrs 176,360 2,997,379 0.03% 21,163 368,678 7 114
30–39 yrs 130,362 2,160,103 0.08% 15,643 265,693 13 224
40–49 yrs 67,618 1,316,593 0.16% 8,114 161,941 13 261
50–59 yrs 28,397 722,800 0.60% 3,408 88,904 20 529
60–69 yrs 15,225 494,678 1.93% 1,827 60,845 35 1,174
70–79 yrs 5,715 280,394 4.28% 686 34,488 29 1,476
80+ yrs 2,001 152,762 7.80% 240 18,790 19 1,466
Total 832,595 18,273,324 99,911 2,247,619 138 5,295
*Source: 2018 Population and Housing Census. ✟ Estimates derived from Verity, R. et al. (2020). The total number of 
reported COVID-19 deaths on 16th July in Blantyre was 17 and in Malawi was 51.
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(median age 17 years old)12, and the elderly who mostly expe-
rience worse outcomes in other settings11, are 5.1% of the 
population12, largely residing in rural areas. If the prevalence 
of SARS-CoV-2 is very low in rural areas, this may explain the 
low number of deaths, and would strengthen the call to shield 
the elderly18.
This study has some limitations. First, selection bias is likely 
due to the convenience sampling approach; however, target-
ing HCW for regular serosurveys could help predict local 
transmission outbreaks. Second, this serosurvey focused on 
an urban population where Malawi has reported the highest 
concentration of COVID-19 cases. The seroprevalence in the 
rural population remains unknown, but if high, may prompt 
other explanations for the African/Malawi situation. Third, current 
SARS-CoV-2 ELISAs are still undergoing rigorous validation 
and verification in the African settings, hence seroprevalence 
estimates could change with new information on the accuracy 
of the test kits.
In conclusion, our findings indicate a major discrepancy between 
predicted COVID-19 mortality at the observed SARS-CoV-2 
seroprevalence in HCWs with reported COVID-19 deaths in 
urban Malawi. The high seroprevalence estimate implies earlier 
exposure of SARS-CoV-2 than that reported but with slow pro-
gression of the COVID-19 epidemic. Development of locally 
parameterised mathematical models should be prioritised to 
more accurately predict the trajectory of the epidemic in SSA. 
This will allow better evidence-based policy decision-making 
and public health response planning.
Data availability
Figshare: High SARS-CoV-2 seroprevalence in Health Care 
Workers but relatively low numbers of deaths in urban Malawi. 
https://doi.org/10.6084/m9.figshare.12745214.v310
This project contains the following underlying data:
-     PROTECT_FigShare Part 1 31072020.csv
 -     PROTECT_screening_enrolment_data_dictionary 
Figshare 31072020.pdf
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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